Roscovitine confers tumor suppressive effect on therapy-resistant breast tumor cells

Breast Cancer Research

Volumn 13, Issue 3, 2011, Pages

  Nair, Binoj C ^a   Vallabhaneni, Sreeram ^a   Tekmal, Rajeshwar R ^a   Vadlamudi, Ratna K ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTENEDIONE; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR; ESTROGEN RECEPTOR ALPHA; LETROZOLE; ROSCOVITINE; STEROID RECEPTOR COACTIVATOR 3; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CDK2 PROTEIN, HUMAN; COREPRESSOR PROTEIN; ESTROGEN RECEPTOR ALPHA, HUMAN; NCOA3 PROTEIN, HUMAN; PELP1 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PURINE DERIVATIVE; TRANSCRIPTION FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST EPITHELIUM; BREAST TUMOR; CANCER INHIBITION; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CELL STRAIN MCF 7; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; FEMALE; HORMONAL THERAPY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR INTERACTION; MOUSE; NONHUMAN; THERAPY RESISTANCE; TUMOR CELL; XENOGRAFT; ANIMAL; BIOSYNTHESIS; CELL CYCLE; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; METABOLISM; NUDE MOUSE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CO-REPRESSOR PROTEINS; CYCLIN D1; CYCLIN-DEPENDENT KINASE 2; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; MICE; MICE, NUDE; NUCLEAR RECEPTOR COACTIVATOR 3; PROTEIN KINASE INHIBITORS; PURINES; TRANSCRIPTION FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80053209796     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2929     Document Type: Article

References (54)

1. Hall JM, McDonnell DP. Coregulators in nuclear estrogen receptor action: from concept to therapeutic targeting. Mol Interv 2005, 5:343-357. 10.1124/mi.5.6.7, 16394250.
2. Green KA, Carroll JS. Oestrogen-receptor-mediated transcription and the influence of co-factors and chromatin state. Nat Rev Cancer 2007, 7:713-722. 10.1038/nrc2211, 17721435.
3. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999, 17:1474-1481.
4. Hartman J, Strom A, Gustafsson JA. Estrogen receptor beta in breast cancer--diagnostic and therapeutic implications. Steroids 2009, 74:635-641. 10.1016/j.steroids.2009.02.005, 19463683.
5. Moy B, Goss PE. Estrogen receptor pathway: resistance to endocrine therapy and new therapeutic approaches. Clin Cancer Res 2006, 12:4790-4793. 10.1158/1078-0432.CCR-06-1535, 16914563.
6. Riggins RB, Schrecengost RS, Guerrero MS, Bouton AH. Pathways to tamoxifen resistance. Cancer Lett 2007, 256:1-24. 10.1016/j.canlet.2007.03.016, 2533271, 17475399.
7. Britton DJ, Hutcheson IR, Knowlden JM, Barrow D, Giles M, McClelland RA, Gee JM, Nicholson RI. Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res Treat 2006, 96:131-146. 10.1007/s10549-005-9070-2, 16261397.
8. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004, 96:926-935. 10.1093/jnci/djh166, 15199112.
9. Dhillon NK, Mudryj M. Ectopic expression of cyclin E in estrogen responsive cells abrogates antiestrogen mediated growth arrest. Oncogene 2002, 21:4626-4634. 10.1038/sj.onc.1205576, 12096339.
10. Louie MC, McClellan A, Siewit C, Kawabata L. Estrogen receptor regulates E2F1 expression to mediate tamoxifen resistance. Mol Cancer Res 2010, 8:343-352. 10.1158/1541-7786.MCR-09-0395, 20215421.
11. Nair BC, Vadlamudi RK. Regulation of hormonal therapy resistance by cell cycle machinery. Gene Ther Mol Biol 2008, 12:395. 2817953, 20148177.
12. Sherr CJ. Cancer cell cycles. Science 1996, 274:1672-1677. 10.1126/science.274.5293.1672, 8939849.
13. Rogatsky I, Trowbridge JM, Garabedian MJ. Potentiation of human estrogen receptor alpha transcriptional activation through phosphorylation of serines 104 and 106 by the cyclin A-CDK2 complex. J Biol Chem 1999, 274:22296-22302. 10.1074/jbc.274.32.22296, 10428798.
14. Trowbridge JM, Rogatsky I, Garabedian MJ. Regulation of estrogen receptor transcriptional enhancement by the cyclin A/Cdk2 complex. Proc Natl Acad Sci USA 1997, 94:10132-10137. 10.1073/pnas.94.19.10132, 23327, 9294175.
15. Bosco EE, Wang Y, Xu H, Zilfou JT, Knudsen KE, Aronow BJ, Lowe SW, Knudsen ES. The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. J Clin Invest 2007, 117:218-228. 10.1172/JCI28803, 1679964, 17160137.
16. Fischer PM, Gianella-Borradori A. Recent progress in the discovery and development of cyclin-dependent kinase inhibitors. Expert Opin Investig Drugs 2005, 14:457-477. 10.1517/13543784.14.4.457, 15882121.
17. Benson C, White J, De BJ, O'Donnell A, Raynaud F, Cruickshank C, McGrath H, Walton M, Workman P, Kaye S, Cassidy J, Gianella-Borradori A, Judson I, Twelves C. A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer 2007, 96:29-37. 10.1038/sj.bjc.6603509, 2360206, 17179992.
18. Guzi T. CYC-202 Cyclacel. Curr Opin Investig Drugs 2004, 5:1311-1318.
19. Vita M, bdel-Rehim M, Olofsson S, Hassan Z, Meurling L, Siden A, Sidén M, Pettersson T, Hassan M. Tissue distribution, pharmacokinetics and identification of roscovitine metabolites in rat. Eur J Pharm Sci 2005, 25:91-103. 10.1016/j.ejps.2005.02.001, 15854805.
20. Wojciechowski J, Horky M, Gueorguieva M, Wesierska-Gadek J. Rapid onset of nucleolar disintegration preceding cell cycle arrest in roscovitine-induced apoptosis of human MCF-7 breast cancer cells. Int J Cancer 2003, 106:486-495. 10.1002/ijc.11290, 12845642.
21. Wesierska-Gadek J, Gueorguieva M, Horky M. Roscovitine-induced up-regulation of p53AIP1 protein precedes the onset of apoptosis in human MCF-7 breast cancer cells. Mol Cancer Ther 2005, 4:113-124. 10.4161/cbt.4.1.1446, 15657359.
22. Appleyard MV, O'Neill MA, Murray KE, Paulin FE, Bray SE, Kernohan NM, Levison DA, Lane DP, Thompson AM. Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model. Int J Cancer 2009, 124:465-472. 10.1002/ijc.23938, 19003963.
23. Maggiorella L, Aubel C, Haton C, Milliat F, Connault E, Opolon P, Deutsch E, Bourhis J. Cooperative effect of roscovitine and irradiation targets angiogenesis and induces vascular destabilization in human breast carcinoma. Cell Prolif 2009, 42:38-48. 10.1111/j.1365-2184.2008.00570.x, 19143762.
24. Nabha SM, Glaros S, Hong M, Lykkesfeldt AE, Schiff R, Osborne K, Reddy KB. Upregulation of PKC-delta contributes to antiestrogen resistance in mammary tumor cells. Oncogene 2005, 24:3166-3176. 10.1038/sj.onc.1208502, 15735693.
25. Macedo LF, Sabnis G, Brodie A. Preclinical modeling of endocrine response and resistance: focus on aromatase inhibitors. Cancer 2008, 112:679-688. 10.1002/cncr.23191, 18072255.
26. Wesierska-Gadek J, Kramer MP, Maurer M. Resveratrol modulates roscovitine-mediated cell cycle arrest of human MCF-7 breast cancer cells. Food Chem Toxicol 2008, 46:1327-1333. 10.1016/j.fct.2007.09.004, 17933449.
27. Nair BC, Nair SS, Chakravarty D, Challa R, Manavathi B, Yew PR, Kumar R, Tekmal RR, Vadlamudi RK. Cyclin-dependent kinase-mediated phosphorylation plays a critical role in the oncogenic functions of PELP1. Cancer Res 2010, 70:7166-7175. 10.1158/0008-5472.CAN-10-0628, 20807815.
28. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004, 96:926-935. 10.1093/jnci/djh166, 15199112.
29. Long BJ, Jelovac D, Handratta V, Thiantanawat A, MacPherson N, Ragaz J, Goloubeva OG, Brodie AM. Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model. J Natl Cancer Inst 2004, 96:456-465. 10.1093/jnci/djh076, 15026471.
30. McClue SJ, Blake D, Clarke R, Cowan A, Cummings L, Fischer PM, MacKenzie M, Melville J, Stewart K, Wang S, Zhelev N, Zheleva D, Lane DP. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer 2002, 102:463-468. 10.1002/ijc.10738, 12432547.
31. Louie MC, Zou JX, Rabinovich A, Chen HW. ACTR/AIB1 functions as an E2F1 coactivator to promote breast cancer cell proliferation and antiestrogen resistance. Mol Cell Biol 2004, 24:5157-5171. 10.1128/MCB.24.12.5157-5171.2004, 419858, 15169882.
32. Balasenthil S, Vadlamudi RK. Functional interactions between the estrogen receptor coactivator PELP1/MNAR and retinoblastoma protein. J Biol Chem 2003, 278:22119-22127. 10.1074/jbc.M212822200, 1262660, 12682072.
33. Katzenellenbogen BS, Katzenellenbogen JA. Biomedicine. Defining the "S" in SERMs. Science 2002, 295:2380-2381. 10.1126/science.1070442, 11923515.
34. Bhatnagar AS. The discovery and mechanism of action of letrozole. Breast Cancer Res Treat 2007, 105(Suppl 1):7-17. 2001216, 17912633.
35. Rau KM, Kang HY, Cha TL, Miller SA, Hung MC. The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers. Endocr Relat Cancer 2005, 12:511-532. 10.1677/erc.1.01026, 16172190.
36. Johnston SR. Acquired tamoxifen resistance in human breast cancer--potential mechanisms and clinical implications. Anticancer Drugs 1997, 8:911-930. 10.1097/00001813-199711000-00002, 9436634.
37. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009, 9:153-166. 10.1038/nrc2602, 19238148.
38. Maurer M, Komina O, Wesierska-Gadek J. Roscovitine differentially affects asynchronously growing and synchronized human MCF-7 breast cancer cells. Ann N Y Acad Sci 2009, 1171:250-256. 10.1111/j.1749-6632.2009.04717.x, 19723062.
39. Mgbonyebi OP, Russo J, Russo IH. Roscovitine induces cell death and morphological changes indicative of apoptosis in MDA-MB-231 breast cancer cells. Cancer Res 1999, 59:1903-1910.
40. Chopin V, Toillon RA, Jouy N, Le B, X. P21(WAF1/CIP1) is dispensable for G1 arrest, but indispensable for apoptosis induced by sodium butyrate in MCF-7 breast cancer cells. Oncogene 2004, 23:21-29. 10.1038/sj.onc.1207020, 14712207.
41. Meijer L, Borgne A, Mulner O, Chong JP, Blow JJ, Inagaki N, Delcros JG, Moulinoux JP. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 1997, 243:527-536. 10.1111/j.1432-1033.1997.t01-2-00527.x, 9030781.
42. Akli S, Bui T, Wingate H, Biernacka A, Moulder S, Tucker SL, Hunt KK, Keyomarsi K. Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors. Clin Cancer Res 2010, 16:1179-1190. 10.1158/1078-0432.CCR-09-1787, 2822889, 20145171.
43. Span PN, Tjan-Heijnen VC, Manders P, Beex LV, Sweep CG. Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer. Oncogene 2003, 22:4898-4904. 10.1038/sj.onc.1206818, 12894232.
44. Desmedt C, Ouriaghli FE, Durbecq V, Soree A, Colozza MA, Azambuja E, Paesmans M, Larsimont D, Buyse M, Harris A, Piccart M, Martiat P, Sotiriou C. Impact of cyclins E, neutrophil elastase and proteinase 3 expression levels on clinical outcome in primary breast cancer patients. Int J Cancer 2006, 119:2539-2545. 10.1002/ijc.22149, 16929516.
45. Porter DC, Zhang N, Danes C, McGahren MJ, Harwell RM, Faruki S, Keyomarsi K. Tumor-specific proteolytic processing of cyclin E generates hyperactive lower-molecular-weight forms. Mol Cell Biol 2001, 21:6254-6269. 10.1128/MCB.21.18.6254-6269.2001, 87349, 11509668.
46. Akli S, Zheng PJ, Multani AS, Wingate HF, Pathak S, Zhang N, Tucker SL, Chang S, Keyomarsi K. Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer. Cancer Res 2004, 64:3198-3208. 10.1158/0008-5472.CAN-03-3672, 15126360.
47. Michalides R, van TH, Balkenende A, Vermorken JB, Benraadt J, Huldij J, van Diest P. Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment. Br J Cancer 2002, 86:402-408. 10.1038/sj.bjc.6600072, 2375223, 11875707.
48. Cariou S, Donovan JC, Flanagan WM, Milic A, Bhattacharya N, Slingerland JM. Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. Proc Natl Acad Sci USA 2000, 97:9042-9046. 10.1073/pnas.160016897, 16818, 10908655.
49. Abukhdeir AM, Vitolo MI, Argani P, De Marzo AM, Karakas B, Konishi H, Gustin JP, Lauring J, Garay JP, Pendleton C, Konishi Y, Blair BG, Brenner K, Garrett-Mayer E, Carraway H, Bachman KE, Park BH. Tamoxifen-stimulated growth of breast cancer due to p21 loss. Proc Natl Acad Sci USA 2008, 105:288-293. 10.1073/pnas.0710887105, 2224203, 18162533.
50. Varma H, Skildum AJ, Conrad SE. Functional ablation of pRb activates Cdk2 and causes antiestrogen resistance in human breast cancer cells. PLoS ONE 2007, 2:e1256. 10.1371/journal.pone.0001256, 2092387, 18060053.
51. Dai H, van't VL, Lamb J, He YD, Mao M, Fine BM, Bernards R, van de Vijver M, Deutsch P, Sachs A, Stoughton R, Friend S. A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. Cancer Res 2005, 65:4059-4066. 10.1158/0008-5472.CAN-04-3953, 15899795.
52. Kim SJ, Nakayama S, Miyoshi Y, Taguchi T, Tamaki Y, Matsushima T, Torikoshi Y, Tanaka S, Yoshida T, Ishihara H, Noguchi S. Determination of the specific activity of CDK1 and CDK2 as a novel prognostic indicator for early breast cancer. Ann Oncol 2008, 19:68-72. 10.1093/annonc/mdn314, 17956886.
53. Wesierska-Gadek J, Gritsch D, Zulehner N, Komina O, Maurer M. Roscovitine, a selective CDK inhibitor, reduces the basal and estrogen-induced phosphorylation of ER-alpha in human ER-positive breast cancer cells. J Cell Biochem 2011, 112:761-772. 10.1002/jcb.23004, 21328450.
54. Ortiz-Ferron G, Yerbes R, Eramo A, Lopez-Perez AI, De MR, Lopez-Rivas A. Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism. Cell Res 2008, 18:664-676. 10.1038/cr.2008.54, 18458681.